Seroprevalence of pertussis in the Gambia: Eevidence for continued circulation of bordetella pertussis despite high vaccination rates

Pediatric Infectious Disease Journal

Volumn 34, Issue 4, 2015, Pages 333-338

  Scott, Susana ^a,b   Van Der Sande, Marianne ^c,d   Faye Joof, Tisbeh ^a   Mendy, Maimuna ^e   Sanneh, Bakary ^a   Barry Jallow, Fatou ^a   De Melker, Hester ^c   Van Der Klis, Fiona ^c   Van Gageldonk, Pieter ^c   Mooi, Frits ^c   Kampmann, Beate ^a,f  

^a Medical Research Council (MRC) Unit The Gambia   (Gambia)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^e INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^f IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

pertussis; seroprevalence; sub Saharan Africa; vaccine; whooping cough

Indexed keywords

IMMUNOGLOBULIN G; PERTUSSIS TOXIN; ANTITOXIN; BACTERIUM ANTIBODY;

ADOLESCENT; ADULT; AGE; AGED; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; BIRTH ORDER; BORDETELLA PERTUSSIS; CHILD; CONCENTRATION (PARAMETERS); CROSS-SECTIONAL STUDY; ETHNIC GROUP; FEMALE; GAMBIA; GENDER; GROUPS BY AGE; HOUSEHOLD; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; INCIDENCE; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; PERTUSSIS; PRIORITY JOURNAL; REINFECTION; RURAL POPULATION; SEROPREVALENCE; SIBLING; VACCINATION; BLOOD; COHORT ANALYSIS; EPIDEMIOLOGY; IMMUNOLOGY; MIDDLE AGED; PRESCHOOL CHILD; PROSPECTIVE STUDY; VERY ELDERLY; WHOOPING COUGH; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, BACTERIAL; ANTITOXINS; BORDETELLA PERTUSSIS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; GAMBIA; HUMANS; IMMUNOGLOBULIN G; INCIDENCE; MALE; MIDDLE AGED; PERTUSSIS TOXIN; PROSPECTIVE STUDIES; SEROEPIDEMIOLOGIC STUDIES; WHOOPING COUGH; YOUNG ADULT;

EID: 84937540878     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0000000000000576     Document Type: Article

References (30)

1. Pertussis vaccines: WHO position paper. Wkly Epidemiol Rec. 2010;85:385-400.
2. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2095-128.
3. Wood N, McIntyre P. Pertussis: review of epidemiology, diagnosis, management and prevention. Paediatr Respir Rev. 2008;9:201-211.
4. Galanis E, King AS, Varughese P, et al. investigators I. Changing epidemiology and emerging risk groups for pertussis. CMAJ. 2006;174:451-452.
5. Celentano LP, Massari M, Paramatti D, et al. Resurgence of pertussis in Europe. Pediatr Infect Dis J. 2005;24:761-765.
6. Mooi FR, Van Der Maas NA, De Melker HE. Pertussis resurgence: waning immunity and pathogen adaptation-Two sides of the same coin. Epidemiol Infect. 2014;142:685-694.
7. Liko J, Robison SG, Cieslak PR. Priming with whole-cell versus acellular pertussis vaccine. N Engl J Med. 2013;368:581-582.
8. Warfel JM, Zimmerman LI, Merkel TJ. Acellular pertussis vaccines protect against disease but fail to prevent infection and transmission in a nonhuman primate model. Proc Natl Acad Sci USA. 2014;111:787-792.
9. Sheridan SL, Ware RS, Grimwood K, et al. Number and order of whole cell pertussis vaccines in infancy and disease protection. JAMA. 2012;308:454-456.
10. Skowronski DM, De Serres G, MacDonald D, et al. The changing age and seasonal profile of pertussis in Canada. J Infect Dis. 2002;185:1448-1453.
11. de Greeff SC, de Melker HE, van Gageldonk PG, et al. Seroprevalence of pertussis in The Netherlands: evidence for increased circulation of Bordetella pertussis. PLoS One. 2010;5:e14183.
12. de Greeff SC, Mooi FR, Westerhof A, et al. Pertussis disease burden in the household: how to protect young infants. Clin Infect Dis. 2010;50: 1339-1345.
13. Kowalzik F, Barbosa AP, Fernandes VR, et al. Prospective multinational study of pertussis infection in hospitalized infants and their household contacts. Pediatr Infect Dis J. 2007;26:238-242.
14. Tanaka M, Vitek CR, Pascual FB, et al. Trends in pertussis among infants in the United States, 1980-1999. JAMA. 2003;290:2968-2975.
15. Simondon F, Preziosi MP, Yam A, et al. A randomized double-blind trial comparing a two-component acellular to a whole-cell pertussis vaccine in Senegal. Vaccine. 1997;15:1606-1612.
16. Preziosi MP, Yam A, Wassilak SG, et al. Epidemiology of pertussis in a West African community before and after introduction of a widespread vaccination program. Am J Epidemiol. 2002;155:891-896.
17. Jusot V, Aberrane S, Ale F, et al. Prevalence of Bordetella infection in a hospital setting in Niamey, Niger. J Trop Pediatr. 2014;60:223-230.
18. Gaayeb L, Sarr JB, Ndiath MO, et al. Seroprevalence of pertussis in Senegal: A prospective study. PLoS One. 2012;7:e48684.
19. Mendy M, Peterson I, Hossin S, et al. Observational study of vaccine efficacy 24 years after the start of hepatitis B vaccination in two Gambian villages: no need for a booster dose. PLoS One. 2013;8:e58029.
20. Scott S, Odutola A, Mackenzie G, et al. Evaluation of the EPI programme in the Gambia: implications of the current immunisation schedule and for new vaccine introduction. PLoS One.2014;9:e107280.
21. van Gageldonk PG, van Schaijk FG, van der Klis FR, et al. Development and validation of a multiplex immunoassay for the simultaneous determination of serum antibodies to Bordetella pertussis, diphtheria and tetanus. J Immunol Methods. 2008;335:79-89.
22. Staros JV, Wright RW, Swingle DM. Enhancement by N-hydroxysulfosuccinimide of water-soluble carbodiimide-mediated coupling reactions. Anal Biochem. 1986;156:220-222.
23. Hallander HO, Ljungman M, Storsaeter J, et al. Kinetics and sensitivity of ELISA IgG pertussis antitoxin after infection and vaccination with Bordetella pertussis in young children. APMIS. 2009;117:797-807.
24. de Melker HE, Versteegh FG, Conyn-Van Spaendonck MA, et al. Specificity and sensitivity of high levels of immunoglobulin G antibodies against pertussis toxin in a single serum sample for diagnosis of infection with Bordetella pertussis. J Clin Microbiol. 2000;38:800-806.
25. de Greeff SC, Teunis P, de Melker HE, et al. Two-component cluster analysis of a large serodiagnostic database for specificity of increases of IgG antibodies against pertussis toxin in paired serum samples and of absolute values in single serum samples. Clin Vaccine Immunol. 2012;19:1452-1456.
26. Hallander HO, Gustafsson L, Ljungman M, et al. Pertussis antitoxin decay after vaccination with DTPa. Response to a first booster dose 3 1/2-6 1/2 years after the third vaccine dose. Vaccine. 2005;23:5359-5364.
27. Mahon BP, Brady MT, Mills KH. Protection against Bordetella pertussis in mice in the absence of detectable circulating antibody: implications for long-Term immunity in children. J Infect Dis. 2000;181:2087-2091.
28. Higgins SC, Jarnicki AG, Lavelle EC, et al. TLR4 mediates vaccine-induced protective cellular immunity to Bordetella pertussis: role of IL-17-producing T cells. J Immunol. 2006;177:7980-7989.
29. European Centre for Disease Prevention and Control. External quality assurance scheme for Bordetella pertussis serology 2013. Stockholm: ECDC;2014.
30. Versteegh FG, Mertens PL, de Melker HE, et al. Age-specific long-Term course of IgG antibodies to pertussis toxin after symptomatic infection with Bordetella pertussis. Epidemiol Infect. 2005;133:737-748.